Stocks and Investing Stocks and Investing
Tue, September 18, 2018
Mon, September 17, 2018

Vamil Divan Maintained (TEVA) at Hold with Increased Target to $26 on, Sep 17th, 2018


Published on 2024-10-26 08:47:32 - WOPRAI, Vamil Divan
  Print publication without navigation


Vamil Divan of Credit Suisse, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Hold with Increased Target from $23 to $26 on, Sep 17th, 2018.

Vamil has made no other calls on TEVA in the last 4 months.



There are 5 other peers that have a rating on TEVA. Out of the 5 peers that are also analyzing TEVA, 4 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Douglas Tsao of "Barclays" Maintained at Hold with Increased Target to $23 on, Monday, August 6th, 2018
  • David Risinger of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Friday, August 3rd, 2018
  • Louise Chen of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $25 on, Monday, July 16th, 2018
  • Jacob Hughes of "Wells Fargo" Upgraded from Sell to Hold on, Monday, June 18th, 2018


This is the rating of the analyst that currently disagrees with Vamil


  • Liav Abraham of "Citigroup" Maintained at Strong Buy with Increased Target to $25 on, Thursday, May 31st, 2018
Contributing Sources